Modality
ADC
MOA
Anti-Tau
Target
PD-1
Pathway
Amyloid
Cervical CaPNH
Development Pipeline
Preclinical
Aug 2017
→ Sep 2030
PreclinicalCurrent
NCT08381894
1,293 pts·PNH
2017-08→2030-09·Recruiting
1,293 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-12-279mo awayPh1 Dose Esc· Cervical Ca
2030-09-254.5y awayInterim· PNH
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Preclinical
Recruit…
Catalysts
Ph1 Dose Esc
2026-12-27 · 9mo away
Cervical Ca
Interim
2030-09-25 · 4.5y away
PNH
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08381894 | Preclinical | PNH | Recruiting | 1293 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| MRN-8133 | Moderna | Phase 2 | PD-1 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 |